Abattis Bioceuticals (ATTBF) 0.4300 $ATTBF
Abattis Announces Grant of Stock Options
ACCESSWIRE - Wed Aug 13, 7:43PM CDT
Vancouver, BC / ACCESSWIRE / August 13, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), the Company is pleased to announce that, in compliance with the Company's option plan, the Company has granted 455,000 incentive stock options to certain of its directors, officers and consultants, with each option being exercisable into a common share of Abattis at $0.43 per share for a period of five years.
Abattis Appoints Jason Anderson as VP of Finance
ACCESSWIRE - Fri Aug 08, 3:47PM CDT
Vancouver, BC / ACCESSWIRE / August 8, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services to medicinal markets in North American, today announced the appointment of Jason Anderson, CA, CFA as Vice President of Finance.
Abattis' Biocube Licenses Terrasphere Vertical Farming Technology
ACCESSWIRE - Wed Aug 06, 8:07AM CDT
Vancouver, BC / ACCESSWIRE / August 6, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, today announced that Biocube Green Grow Systems Corp. ("Biocube" , its wholly owned subsidiary, entered into a worldwide non-exclusive licensing agreement with TerraSphere Systems LLC ("TerraSphere" for the company's proprietary and patented vertical farming technology. The TerraSphere license complements Biocube's previously announced sublicensing agreement for Vertical Design Ltd.'s ("VDL" vertical farming technology.
Abattis Enters Into US$5 Million Standby Equity Purchase Agreement with Kodiak Capital Group, LLC
ACCESSWIRE - Tue Aug 05, 8:11AM CDT
Vancouver, BC / ACCESSWIRE / August 5, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, including medical marihuana, announced that it has entered into a US$5 million standby equity financing agreement with Kodiak Capital Group, LLC, a Newport Beach, CA-based institutional investor. The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC" covering the Abattis shares that may be issued to Kodiak under this financing. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of one year to sell up to US$5 million of common shares to Kodiak.
Abattis Sub-Licenses Vertical Grow Systems to Biocube
ACCESSWIRE - Thu Jul 31, 7:04AM CDT
Vancouver, BC / ACCESSWIRE / July 31, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), today announced that it has entered into a sub-licensing agreement with its subsidiary, Biocube Green Grow Systems Corp. ("Biocube" , for the non-exclusive use of Vertical Design Ltd.'s ("VDL" vertical growing systems for which Abattis owns certain exclusive worldwide rights. Under the terms of the agreement, Biocube has agreed to pay Abattis certain licensing fees and ongoing royalties for products grown and sold within the pharmaceutical, nutraceutical, cosmetic, and wellness markets. The company also wishes to clarify recent confusion about the ownership of the rights and uses to the VDL growing technology that has been created by Affinor Growers, (CSE: AFI) (OTCQB: RSSFF) the parent of VDL.
Abattis Makes History as First Marijuana Stock to List on Prestigious OTCQX
ACCESSWIRE - Tue Jul 15, 7:00AM CDT
Whitefish, MT / July 15, 2014 / Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary products and services to the North American cannabis industry, added to its growing list of accomplishments by becoming the first cannabis stock to list on the prestigious OTCQX tier of the OTC Markets on Monday, July 14, 2014.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Abattis Begins Trading On The OTCQX
ACCESSWIRE - Mon Jul 14, 5:17AM CDT
Vancouver, BC / ACCESSWIRE / July 14, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that it began trading on the OTCQX marketplace.
OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX®
PR Newswire - Fri Jul 11, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Abattis Bioceuticals Corp. (CSE: ATT; OTCQX: ATTBF), a specialty biotechnology company, has qualified to trade on OTCQX®, the best marketplace.
Abattis Information Available on S&P Capital IQ
ACCESSWIRE - Mon Jul 07, 12:21AM CDT
Vancouver, BC / ACCESSWIRE / July 6, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio---similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its company information would be made available via S&P Capital IQ Corporation Record's Listing Program. This is one of the final steps in the Company elevating to the OTC QX in the upcoming months.
Correction To Earlier News: Abattis Names Brazos Minshew The Next President Of Biocell
ACCESSWIRE - Wed Jul 02, 10:53PM CDT
Vancouver, BC / ACCESSWIRE / July 02, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Brazos Minshew, Chief Executive Officer of Samuel J. Brant, LLC and would like to issue the following correction.
Abattis Names Brazos Minshew The Next President Of Biocell
ACCESSWIRE - Wed Jul 02, 7:23PM CDT
Vancouver, BC / ACCESSWIRE / July 02, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Brazos Minshew, Chief Executive Officer of Samuel J. Brant, LLC, former Chief Science Officer of TriVita, Inc., former Chief Executive Officer of Therapy Alternatives and Director of Marketing for Tiena Health, will assume the role of President of BioCell Labs, a wholly-owned subsidiary of Abattis Bioceuticals Corp. effective July 1, 2014. He will succeed Mike Withrow, who is resigning his role of President at BioCell to focus on leadership as Chief Executive Officer of Abattis Bioceuticals Corp. He will remain as Chairman of BioCell.
Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Abattis Bioceuticals to be Featured on CEO Clips Airing on BNN
ACCESSWIRE - Fri Jun 27, 3:55PM CDT
Vancouver, BC / ACCESSWIRE / June 27, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that CEO Clips will be running a series of commercials on Canada's Business News Network ("BNN" advertising the Company's upcoming BTV Business Television segment are to be shown on July 19th and July 20th.
Abattis Bioceuticals Receives Breakthrough Nitric Oxide WIPO Patent Publication
ACCESSWIRE - Mon Jun 23, 4:57PM CDT
Vancouver, BC / ACCESSWIRE / June 23, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its wholly-owned subsidiary, BioCell Laboratories, Inc. ("BioCell" , was awarded an International Patent for refining the optimum natural sources of nitric oxide in the human body.
Abattis Bioceuticals Adopts New Policies, Changes Auditor & Adds New Board Members at Annual General Meeting of Shareholders
ACCESSWIRE - Thu Jun 19, 9:34PM CDT
Vancouver, BC / ACCESSWIRE/ June 19, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its previous Board has been re-elected and two industry experts have been added to the Company's Board of Directors and shareholders have also approved the adoption of new policies at the Company's Annual General Meeting of Shareholders ("AGM" held on June 18, 2014.
Novus (NDEV) Aims to Fill Key Void in Cannabis Industry
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / The U.S. legal cannabis industry is expected to reach $2.34 billion in size by the end of the year, according to ArcView Market Research. With additional states expected to legalize the drug over the next five years, the same group believes that the U.S. industry could reach $10.2 billion in size by 2018. These growth rates have attracted both investors and lawmakers interested in shoring up tax revenue.
Abattis Launches a New Corporate Website
ACCESSWIRE - Fri Jun 13, 3:38PM CDT
Vancouver, BC / ACCESSWIRE / June 13, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced the launch of its newly redesigned corporate website.
Abattis Announces Phytalab CSO Presents at 24th Annual ICRS Meeting in Italy
ACCESSWIRE - Wed Jun 11, 8:04AM CDT
Vancouver, BC / ACCESSWIRE / Wednesday June 11, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis" (OTC PINK: ATTBF) (CSE: ATT), through its wholly owned Washington subsidiary Abattis Bioceuticals International Inc. is pleased to announce Dr. Sexton, CSO of Phytalab LLC in Kirkland, WA, will have an oral presentation at the upcoming 24th Annual International Cannabinoid Research Society (ICRS) meeting in Baveno Italy. Dr. Sexton has been a member of the ICRS since 2007 and has previously presented for the ICRS. She served on the program committee for this 2014 symposium on Cannabinoids. Her talk is entitled "A MEDICAL ETHNOGRAPHIC REPORT OF CANNABIS USE IN PEDIATRIC INTRACTABLE EPILEPSY (IE) PATIENTS" and will be presented during a session on "CNS and Psychiatric Issues", June 30th. Dr. Sexton will also be chairing a session with Luciano di Petrocellis entitled " Beyond THC: Cannabidiol and Other Components." The five-day conference is the meeting for a group of over 500 active researchers in all fields of the cannabinoids and related bioactive lipids. Dr. Sexton commented "I am honored that ICRS President Ethan Russo gave me the opportunity to participate in this historic organization, and proud to have earned the opportunity to discuss research with a fabulous collection of thinkers".
Abattis Announces Grant of Stock Options
ACCESSWIRE - Wed Aug 13, 7:43PM CDT
Vancouver, BC / ACCESSWIRE / August 13, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), the Company is pleased to announce that, in compliance with the Company's option plan, the Company has granted 455,000 incentive stock options to certain of its directors, officers and consultants, with each option being exercisable into a common share of Abattis at $0.43 per share for a period of five years. Abattis Appoints Jason Anderson as VP of Finance
ACCESSWIRE - Fri Aug 08, 3:47PM CDT
Vancouver, BC / ACCESSWIRE / August 8, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services to medicinal markets in North American, today announced the appointment of Jason Anderson, CA, CFA as Vice President of Finance. Abattis' Biocube Licenses Terrasphere Vertical Farming Technology
ACCESSWIRE - Wed Aug 06, 8:07AM CDT
Vancouver, BC / ACCESSWIRE / August 6, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, today announced that Biocube Green Grow Systems Corp. ("Biocube" , its wholly owned subsidiary, entered into a worldwide non-exclusive licensing agreement with TerraSphere Systems LLC ("TerraSphere" for the company's proprietary and patented vertical farming technology. The TerraSphere license complements Biocube's previously announced sublicensing agreement for Vertical Design Ltd.'s ("VDL" vertical farming technology. Abattis Enters Into US$5 Million Standby Equity Purchase Agreement with Kodiak Capital Group, LLC
ACCESSWIRE - Tue Aug 05, 8:11AM CDT
Vancouver, BC / ACCESSWIRE / August 5, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, including medical marihuana, announced that it has entered into a US$5 million standby equity financing agreement with Kodiak Capital Group, LLC, a Newport Beach, CA-based institutional investor. The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC" covering the Abattis shares that may be issued to Kodiak under this financing. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of one year to sell up to US$5 million of common shares to Kodiak. Abattis Sub-Licenses Vertical Grow Systems to Biocube
ACCESSWIRE - Thu Jul 31, 7:04AM CDT
Vancouver, BC / ACCESSWIRE / July 31, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), today announced that it has entered into a sub-licensing agreement with its subsidiary, Biocube Green Grow Systems Corp. ("Biocube" , for the non-exclusive use of Vertical Design Ltd.'s ("VDL" vertical growing systems for which Abattis owns certain exclusive worldwide rights. Under the terms of the agreement, Biocube has agreed to pay Abattis certain licensing fees and ongoing royalties for products grown and sold within the pharmaceutical, nutraceutical, cosmetic, and wellness markets. The company also wishes to clarify recent confusion about the ownership of the rights and uses to the VDL growing technology that has been created by Affinor Growers, (CSE: AFI) (OTCQB: RSSFF) the parent of VDL. Abattis Makes History as First Marijuana Stock to List on Prestigious OTCQX
ACCESSWIRE - Tue Jul 15, 7:00AM CDT
Whitefish, MT / July 15, 2014 / Abattis Bioceuticals Corp. (OTC: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary products and services to the North American cannabis industry, added to its growing list of accomplishments by becoming the first cannabis stock to list on the prestigious OTCQX tier of the OTC Markets on Monday, July 14, 2014.
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.
Abattis Begins Trading On The OTCQX
ACCESSWIRE - Mon Jul 14, 5:17AM CDT
Vancouver, BC / ACCESSWIRE / July 14, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTCQX: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that it began trading on the OTCQX marketplace. OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX®
PR Newswire - Fri Jul 11, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Abattis Bioceuticals Corp. (CSE: ATT; OTCQX: ATTBF), a specialty biotechnology company, has qualified to trade on OTCQX®, the best marketplace.
Abattis Information Available on S&P Capital IQ
ACCESSWIRE - Mon Jul 07, 12:21AM CDT
Vancouver, BC / ACCESSWIRE / July 6, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio---similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its company information would be made available via S&P Capital IQ Corporation Record's Listing Program. This is one of the final steps in the Company elevating to the OTC QX in the upcoming months. Correction To Earlier News: Abattis Names Brazos Minshew The Next President Of Biocell
ACCESSWIRE - Wed Jul 02, 10:53PM CDT
Vancouver, BC / ACCESSWIRE / July 02, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Brazos Minshew, Chief Executive Officer of Samuel J. Brant, LLC and would like to issue the following correction. Abattis Names Brazos Minshew The Next President Of Biocell
ACCESSWIRE - Wed Jul 02, 7:23PM CDT
Vancouver, BC / ACCESSWIRE / July 02, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Brazos Minshew, Chief Executive Officer of Samuel J. Brant, LLC, former Chief Science Officer of TriVita, Inc., former Chief Executive Officer of Therapy Alternatives and Director of Marketing for Tiena Health, will assume the role of President of BioCell Labs, a wholly-owned subsidiary of Abattis Bioceuticals Corp. effective July 1, 2014. He will succeed Mike Withrow, who is resigning his role of President at BioCell to focus on leadership as Chief Executive Officer of Abattis Bioceuticals Corp. He will remain as Chairman of BioCell. Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Abattis Bioceuticals to be Featured on CEO Clips Airing on BNN
ACCESSWIRE - Fri Jun 27, 3:55PM CDT
Vancouver, BC / ACCESSWIRE / June 27, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that CEO Clips will be running a series of commercials on Canada's Business News Network ("BNN" advertising the Company's upcoming BTV Business Television segment are to be shown on July 19th and July 20th. Abattis Bioceuticals Receives Breakthrough Nitric Oxide WIPO Patent Publication
ACCESSWIRE - Mon Jun 23, 4:57PM CDT
Vancouver, BC / ACCESSWIRE / June 23, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its wholly-owned subsidiary, BioCell Laboratories, Inc. ("BioCell" , was awarded an International Patent for refining the optimum natural sources of nitric oxide in the human body. Abattis Bioceuticals Adopts New Policies, Changes Auditor & Adds New Board Members at Annual General Meeting of Shareholders
ACCESSWIRE - Thu Jun 19, 9:34PM CDT
Vancouver, BC / ACCESSWIRE/ June 19, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC Pink: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that its previous Board has been re-elected and two industry experts have been added to the Company's Board of Directors and shareholders have also approved the adoption of new policies at the Company's Annual General Meeting of Shareholders ("AGM" held on June 18, 2014. Novus (NDEV) Aims to Fill Key Void in Cannabis Industry
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / The U.S. legal cannabis industry is expected to reach $2.34 billion in size by the end of the year, according to ArcView Market Research. With additional states expected to legalize the drug over the next five years, the same group believes that the U.S. industry could reach $10.2 billion in size by 2018. These growth rates have attracted both investors and lawmakers interested in shoring up tax revenue.
Abattis Launches a New Corporate Website
ACCESSWIRE - Fri Jun 13, 3:38PM CDT
Vancouver, BC / ACCESSWIRE / June 13, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced the launch of its newly redesigned corporate website. Abattis Announces Phytalab CSO Presents at 24th Annual ICRS Meeting in Italy
ACCESSWIRE - Wed Jun 11, 8:04AM CDT
Vancouver, BC / ACCESSWIRE / Wednesday June 11, 2014 / Abattis Bioceuticals Corp. (the "Company" or "Abattis"
(OTC PINK: ATTBF) (CSE: ATT), through its wholly owned Washington subsidiary Abattis Bioceuticals International Inc. is pleased to announce Dr. Sexton, CSO of Phytalab LLC in Kirkland, WA, will have an oral presentation at the upcoming 24th Annual International Cannabinoid Research Society (ICRS) meeting in Baveno Italy. Dr. Sexton has been a member of the ICRS since 2007 and has previously presented for the ICRS. She served on the program committee for this 2014 symposium on Cannabinoids. Her talk is entitled "A MEDICAL ETHNOGRAPHIC REPORT OF CANNABIS USE IN PEDIATRIC INTRACTABLE EPILEPSY (IE) PATIENTS" and will be presented during a session on "CNS and Psychiatric Issues", June 30th. Dr. Sexton will also be chairing a session with Luciano di Petrocellis entitled " Beyond THC: Cannabidiol and Other Components." The five-day conference is the meeting for a group of over 500 active researchers in all fields of the cannabinoids and related bioactive lipids. Dr. Sexton commented "I am honored that ICRS President Ethan Russo gave me the opportunity to participate in this historic organization, and proud to have earned the opportunity to discuss research with a fabulous collection of thinkers". 
